Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

1.71
Delayed Data
As of Dec 15
 -0.02 / -1.16%
Today’s Change
1.50
Today|||52-Week Range
10.90
-67.67%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$20.4M

Company Description

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products includes CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Contact Information

Cyclacel Pharmaceuticals, Inc.
200 Connell Drive
Berkeley Heights New Jersey 07922
P:(908) 517-7330
Investor Relations:

Employees

Shareholders

Mutual fund holders3.40%
Other institutional22.97%
Individual stakeholders11.80%

Top Executives

Spiro RombotisPresident, Chief Executive Officer & Director
Paul McBarronCOO, CFO, Secretary, Director & Executive VP
David GloverChief Scientist
Susan DavisSenior Director-Business Development
Judy ChiaoVP-Clinical Development & Regulatory Affairs